Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propylthiouracil
Drug ID BADD_D01869
Description A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Indications and Usage Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
Marketing Status approved; investigational
ATC Code H03BA02
DrugBank ID DB00550
KEGG ID D00562
MeSH ID D011441
PubChem ID 657298
TTD Drug ID D00MIN
NDC Product Code 33342-314; 67253-651; 68084-964; 49452-6112; 20012-0001; 0228-2348; 70752-171; 59348-0013; 65319-1059
UNII 721M9407IY
Synonyms Propylthiouracil | 6-Propyl-2-Thiouracil | 6 Propyl 2 Thiouracil
Chemical Information
Molecular Formula C7H10N2OS
CAS Registry Number 51-52-5
SMILES CCCC1=CC(=O)NC(=S)N1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Urine odour abnormal20.02.01.020--Not Available
Antineutrophil cytoplasmic antibody positive13.06.01.012--Not Available
Inflammation10.02.01.089; 08.01.05.0070.009404%Not Available
Disease recurrence08.01.03.0500.014106%Not Available
Salivary gland disorder07.06.02.001--Not Available
Pigmentation disorder23.05.03.001--Not Available
Renal impairment20.01.03.0100.018808%Not Available
Bone marrow failure01.03.03.005--
Liver injury12.01.17.012; 09.01.07.022--Not Available
Organising pneumonia22.01.02.0080.014106%Not Available
Low birth weight baby18.04.02.0030.014106%Not Available
Traumatic liver injury09.01.08.010; 12.01.17.027--Not Available
Acute kidney injury20.01.03.0160.028212%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.014106%Not Available
Granulomatosis with polyangiitis24.12.04.011; 22.01.01.015; 10.02.02.018; 20.05.01.0130.018808%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.009404%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.028212%
Cryoglobulinaemia10.04.04.013; 24.12.04.0070.014106%Not Available
IgA nephropathy20.05.01.016; 10.02.01.0630.009404%Not Available
Live birth18.08.02.0070.014106%Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis24.12.04.002; 10.02.02.0230.206889%Not Available
Iodine allergy10.01.01.0160.009404%Not Available
Pulmonary renal syndrome22.01.01.022; 20.05.01.019; 10.04.04.0170.032914%Not Available
Hypothyroidic goitre14.11.01.053; 05.02.03.0110.009404%Not Available
Therapy non-responder08.06.01.0630.009404%Not Available
The 4th Page    First    Pre   4    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene